| odanacatib (MK-0822) / Merck (MSD) |
| Ongoing | 3 | 5000 | Europe | Odanacatib, MK-0822, Tablet | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | osteoporosis, endocrinology, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2008-004578-42: An Imaging Sub-Study of the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium |
|
|
| | 3 | 400 | Europe | MK-0822; Chemical name N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4\'-(methylsulfo, cholecalciferol (Vitamin D3), MK-0822 | Merck & Co. Inc., Merck & Co., Inc. | Postmenopausal Osteoporosis | | | | |
2008-005874-11: A Substudy to Explore Biomarkers of Physical Function in the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated with Vitamin D and Calcium |
|
|
| Ongoing | 3 | 55 | Europe | | Laboratoires Merck Sharp & Dhome-Chibret | This is an exploratory sub-study of Protocol 018 (Eudract N°2007-002693-66) to identify biomarkers of physical function. This biomarker sub-study will use an ongoing clinical study (Protocol 018) for osteoporosis as a starting point for identification of molecular biomarkers in circulating blood for patient identification and sarcopenia progression. Patients recruited in Protocol 018 are women 65 years of age or older with osteoporosis and either 0 or 1 prior vertebral fracture. | | | | |
2009-011920-69: A Quantitative Computed Tomography (QCT) Sub-Study of the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium |
|
|
| Ongoing | 3 | 20 | Europe | | Merck & Co., Inc. | postmenopausal osteoporosis | | | | |